The receptor for hyaluronan (HA)-mediated motility (RHAMM) controls motility by malignant cells in myeloma and is abnormally expressed on the surface of most malignant B and plasma cells in blood or bone marrow (BM) of patients with multiple myeloma (MM 
M ULTIPLE MYELOMA (MM) is an incurable cancer
characterized by the presence of monoclonal Ig in the blood, lytic bone lesions, and monoclonal plasma cells in the bone marrow (BM). Median survival is approximately 3 years. Compared with its incidence, MM accounts for a disproportionate number of the deaths from hematologic malignancies. Although many patients achieve initial clinical remission, nearly all relapse and become refractory to treatment. 1, 2 The molecular basis of the malignancy is unknown, and no consistent oncogenic or genetic abnormality characterizes all myeloma patients. Although clinically MM is viewed as a disease restricted to the BM, molecular studies confirm it to be a systemic malignancy that includes peripheral blood. Many groups, including ours, have identified clonotypic IgH VDJ among peripheral blood mononuclear cells (PBMC) of MM patients, [3] [4] [5] [6] [7] [8] [9] [10] [11] or purified B cells from MM PBMC. 6, [12] [13] [14] We have identified and verified the IgH VDJ clonal sequences that characterize each MM patient, and have shown that clonotypic B cells are frequent in the circulation of myeloma patients (0.16 ϫ 10 9 /L blood). 12-14 These B cells are late-stage, drugresistant cells with stem-cell-like properties. 6, [12] [13] [14] [15] [16] [17] [18] The majority of B cells in MM PBMC are surface Ig ϩ (sIg), express pan-B cell markers (CD19, CD20, CD24) and by a variety of measures appear to be in an activated late stage of B-cell differentiation. 13, 16, 19, 20 They express the stem-cell marker CD34, 12 and a large constellation of receptors involved in adhesion to endothelium or extracellular matrix (ECM) and in motility. 13, 17, [20] [21] [22] [23] Morphologically and functionally, these B cells are distinct from plasma cells. 17, 24, 25 Both MM B and plasma cells are characterized by their expression of the receptor for hyaluronan (HA)-mediated motility (RHAMM), but only circulating B cells are motile. 17, 22, 24 The heterogeneity in phenotype and morphology seen among these clonotypic B cells, including resting B cells, lymphoblasts, and more differentiated phenotypes, is suggestive of sequentially related cell types resulting from continuous stimulation.
Interactions between HA and RHAMM are required for motile behavior of a wide variety of cells, including sperm, fibroblasts, astrocytes, microglia, and white blood cells. 17, 22, [26] [27] [28] [29] [30] Binding of HA by RHAMM triggers signal transduction, dissolution of focal adhesions, and motility, and is involved in cell cycle control. 24, 26, [31] [32] [33] [34] RHAMM is a glycophosphatidylinositol (GPI)-anchored receptor, lacking both a signal sequence and a transmembrane domain, that is alternatively spliced to yield soluble, cytoplasmic, and surface receptor isoforms. 26, 27 RHAMM mediates motility, is itself oncogenic when overexpressed, and is essential for ras-mediated transformation. 27 Activated normal lymphocytes transiently express a low level of RHAMM. 22, 28 In MM, RHAMM on B and leukemic plasma cells binds HA and mediates HA-dependent motility. 17 Although nonmotile BM-anchored MM plasma cells also express RHAMM, its function on these cells is as yet unknown. The relatively abundant RHAMM on most B and plasma cells in MM, as well as its apparently constitutive functional properties, 17 suggests it may be deregulated or overexpressed, and thus implicated in the malignant process.
In this study, we have characterized the RHAMM expression of malignant B-lineage cells in myeloma by sequencing and mapping the expression patterns of RHAMM transcripts in MM B and plasma cells from patients as compared with malignant B cells in lymphoma and chronic lymphocytic leukemia (CLL) and B cells from normal donors or donors with nonmalignant but activated B cells (Crohn's disease). We find that three distinct RHAMM transcripts are detectable ex vivo in MM B and plasma cells, lymphoma cells, and CLL cells, two of which are novel deletion splice variants. All three forms of RHAMM are detectably overexpressed in malignant B-lineage cells as compared with resting or activated normal B cells.
MATERIALS AND METHODS
Patients. Peripheral blood was obtained from 101 patients with MM, three patients with CLL, eight healthy normal volunteers, and three patients with Crohn's disease after informed consent; BM was obtained from 11 patients with MM. Malignant lymphoma nodes from three patients were pathology specimens obtained after surgery.
Antibodies and reagents. B4-FITC (CD19) was from Coulter (Hialeah, FL). FMC63 (CD19) was from Dr H. Zola Tissue and cell preparations. All cell preparations were used immediately ex vivo. Peripheral blood or BM cells from MM and CLL patients and normal donors or donors with Crohn's disease were collected into heparinized vacutainer tubes, centrifuged over a Ficollhypaque gradient, washed, and resuspended in Trizol (GIBCO-BRL/ Life Technologies, Burlington, Ontario, Canada). Lymphoma nodes were minced to prepare single-cell suspensions, pelleted, and resuspended in Trizol. Only nodes with greater than 50% B cells among lymph node mononuclear cells were used for this study. Our previous work indicated that only B cells in nodes from lymphoma patients expressed surface RHAMM, and that RHAMM was not expressed by normal B or T cells from lymph node. 22 PBMC from B-CLL samples included greater than 98% B cells.
Immunofluorescence and sorting. For phenotypic analysis, MM PBMC or BM cells, or normal PBMC, were stained in two-color immunofluorescence with mAb to CD19 (direct conjugate) and to RHAMM or an IgG1 isotype-matched control (indirect staining) followed by washing, blocking with mouse gamma-globulin, and detection with a goat antimouse Ig fluorescent conjugate, as previously described. 6 Reverse-transcriptase polymerase chain reaction. RNA was extracted using Trizol, resuspended in diethyl pyrocarbonate (DEPC)-treated water, and stored at Ϫ80°C. Next, total RNA (500 ng or 1 µg) was denatured at 70°C for 10 minutes, annealed to 0.5 µmol/L oligo dT15, and reverse-transcribed with 0.5 mmol/L deoxyribonucleoside triphosphates (dNTPs), 0.01 mol/L dithiothreitol (DTT), 200 U Superscript (GIBCO/BRL), and 1ϫ reverse transcriptase (RT) buffer (GIBCO BRL) in a volume of 20 µL at 42°C for 60 minutes, and heat-inactivated at 99°C for 3 minutes. The cDNA template (1 to 4 µL) was amplified in a 50-µL polymerase chain reaction (PCR) mix (Boehringer Mannheim, Laval, Quebec, Canada; BMH) containing 1ϫ PCR buffer, 0.2 mmol/L dNTPs, 0.4 µmol/L upstream and downstream primers, and 1U Taq DNA polymerase. The PCR cycling parameters were denaturation for 5 minutes at 94°C, followed by 35 cycles of denaturation for 1 minute at 94°C, annealing for 30 seconds, and extension at 72°C for 2 minutes, with a final extension period of 7 minutes at 72°C. Primer annealing temperature (T A ) was calculated as
The primers used to amplify RHAMM were as follows: (1) 5Ј GGCCGTCAACATGTCCTTTCCTA, 3Ј TTGGGCTATTTTCCCTT-GAGACTC; (2) 5Ј CAGGTCACCCAAAGGAGTCTCG, 3Ј CAAGCT-CATCCAGTGTTTGC; (3) 5Ј GCAAACACTGGATGAGCTTG, 3Ј TTGCCTTCTTTTAATGGGGTC; (4) 5Ј AGGAGGAACAAGCT-GAAAGG, 3Ј TTCCTGAGCTGCACCATGTT; (5) 5Ј GGCCGTCAA-CATGTCCTTTCCTA, 3Ј ACAGCAACATCAATAACAACAAGA; (6) 5Ј GAGAATTCTAAGCTTGGAGTTG, 3Ј CAAGCTCATCCAGT-GTTTGC; (7) 5Ј TCCTAGAAGAAAAGCTGAAAGGGAA, 3Ј CTTG-GCCGCTTTTTCCTGTAATGA; and (8) 5Ј GTTTCTGGAGCTGGC-CGTC, 3Ј ACTGGTCCTTTCAATACTTCTAAAGT.
Cloning and sequencing. The PCR products were ligated into the PCR TM II or PCR TM2.1 vector and transformed into One ShotTM competent cells with the TA cloning kit according to the manufacturer's instructions (Invitrogen, San Diego, CA). Single bacterial colonies were introduced into a 25-µL PCR reaction mix containing 1ϫ PCR buffer, 0.2 mol/L dNTPs, 0.4 µmol/L upstream and downstream primers, and 0.5 U Taq DNA polymerase. The PCR cycling parameters were bacterial lysis for 10 minutes at 94°C, followed by 25 cycles of denaturation for 1 minute at 94°C, annealing at T A for 30 seconds, and extension at 72°C for 1 minute, with a final extension period of 7 minutes at 72°C. The amplified products were analyzed by agarose gel electrophoresis. The cloned inserts were sequenced with the ABI PRISM TM Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer, Applied Biosystems, Mississauga, Ontario, Canada) Amplification and detection of RHAMM isoforms. Total RNA (500 ng or 1 µg) was prepared and reverse-transcribed as described earlier. To detect RHAMM FL and RHAMM Ϫ48 , 5 µL of cDNA was amplified with RHAMM primer set 1 (described earlier).
To ensure mRNA integrity, 1 µL of cDNA was amplified with histone primers: 5Ј CCACTGAACTTCTGATTCGC, 3Ј GCGTGCTAGCTG-GATGTCTT; or 5 µL of cDNA was amplified with CD19 primers: 5Ј TACTATGGCACTGGCTGCTG, 3Ј CACGTTCCCGTACTGGTTCT.
The amplified products were analyzed on a 1% agarose, ethidium bromide, 50 mmol/L Tris, 45 mmol/L boric acid, 0.5 mmol/L EDTA, pH 8.3 (0.5ϫ TBE) gel.
To detect RHAMM Ϫ147 , 5 µL of cDNA was amplified with RHAMM primer set 3 (described earlier), electrophoresed on a 1% agarose gel, and transferred overnight onto Hybond-N nylon membrane (Amersham Canada Ltd, Oakville, Ontario, Canada). The membrane was prehybridized in 5ϫ SSC, 0.1% N-lauroylsarcosine, 0.2% sodium dodecyl sulfate (SDS), and 2% blocking reagent (BMH) for 1 hour at 65°C and then hybridized to a 20-ng/mL digoxigenin (DIG)-labeled RHAMM probe overnight at 65°C in prehybridization solution. The probe template was amplified from BM plasma-cell cDNA with RHAMM primer set 9: 5Ј GAAAAGTAGTGCTGCTCATACC, 3Ј GGTCTGCAGATCTAGAAG-CATC; and labeled with DIG-11-dUTP with a DIG DNA-labeling kit (BMH) according to the manufacturer's instructions. After hybridization, the membrane was washed once in 2ϫ SSC, 0.1% SDS for 10 minutes at room temperature, twice in 0.1ϫ SSC, 0.1% SDS for 15 minutes at 65°C, blocked with 2% blocking reagent for 30 minutes at room temperature, incubated with 1:5,000 anti-DIG Fab alkaline phosphatase/2% blocking solution for 30 minutes at room temperature, washed twice in 0.1 mol/L maleic acid, 0.1 mol/L NaCl, 0.3% Tween-20 for 15 minutes at room temperature and equilibrated in 0.1 mol/L Tris-HCl, 0.15 mol/L NaCl pH 9. Amplified RHAMM was detected by incubating the membrane with 4.5 µg/mL 4-Nitro blue tetrazolium chloride (NBT), 1.7 µg/mL 5-bromo-4-chloro-3-indolyl-phosphate (BCIP; BMH) in 0.1 mol/L Tris-HCl, 0.15 mol/L NaCl, 0.05 mol/L MgCl 2 pH 9 at room temperature and monitoring color development or by overlaying the membrane with Lumi-phos 530 chemiluminescence substrate sheet (Schleicher & Schuell, Keene, NH) and exposure to Hyperfilm-ECL (Amersham).
Comparison of primer effıciency. The open-reading frame (ORF) of each cloned RHAMM isoform was restriction-digested from the PCR TM II vector with EcoRV plus Kpn I, electrophoresed on a low-meltingpoint agarose gel, and purified with ␤-Agarase (New England Biolabs, Beverly, MA) according to the manufacturer's instructions. RHAMM FL and RHAMM Ϫ48 (100 pg, 10 pg, 1 pg) were amplified with primer set 1, and the products analyzed by electrophoresis on an ethidium bromide- PBMC or BMC were stained in two color immunofluorescence as indicated in Materials and Methods. Files were gated for B or plasma cells and the expression of RHAMM plotted as a histogram (as in Fig  1) , in comparison to identically gated isotype-matched control staining.
*From Turley et al. 22 †P Ͻ .001 as compared with normal B cells.
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For personal use only. on October 23, 2017. by guest www.bloodjournal.org From stained agarose gel. RHAMM FL and RHAMM Ϫ147 (100 pg, 10 pg, 1 pg) were amplified with primer set 3, and the products analyzed by electrophoresis, transfer to a nylon membrane, hybridization to a DIG-labeled RHAMM probe, and chemiluminescent detection as described earlier.
In situ RT-PCR. In situ RT-PCR was as previously described. 12,13 Briefly, normal B cells, MM B cells, and BM plasma cells were purified and stained as described earlier. The cells were fixed in 10% formalin/ PBS overnight and sorted onto In Situ PCR glass slides (Perkin Elmer) at 10,000 cells/spot. Each slide had three spots that included a negative control, which was not reverse-transcribed to confirm digestion of genomic DNA, a positive control with intact genomic DNA, and a test spot. The slides were air-dried, permeabilized with 2 mg/mL pepsin/ 0.01N HCl (BMH) at times optimal for each cell type, normal B cells for 45 minutes, MM B cells for 40 minutes, and MM BM plasma cells for 35 minutes, followed by a 1-minute wash in DEPC-treated water and then 1 minute in 95% ethanol. The negative control and test spot were digested with 1,000 U/mL DNAse I (RNAse-free; BMH) overnight at 37°C followed by a water and ethanol wash. The test sample was reverse transcribed with Superscript according to the manufacturer's recommendations followed by a water and ethanol wash. Amplification was performed on the negative, positive and test spots with an In Situ Core Kit (Perkin Elmer) with direct incorporation of DIG-11-dUTP (BMH). Cycling parameters were denaturation for 5 minutes at 94°C, followed by 25 cycles of denaturation for 1.5 minutes at 94°C, annealing for 1.5 minutes at 65°C, and extension for 2 minutes at 72°C, with a final extension period of 7 minutes at 72°C. The primers used to amplify RHAMM were primer set 10: 5Ј ATCACAAAGATTTAAA-CAACAAAAAGAAT, 3Ј CTTCCATCTTTTCCAACTCAGTTTC.
The slides were washed in 2ϫ SSC (20ϫ SSC ϭ 3 mol/L sodium chloride, 0.3 mol/L sodium citrate, pH 7) for 5 minutes at room temperature, blocked with 0.1ϫ SCC/0.2% bovine serum albumin 
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For personal use only. on October 23, 2017. by guest www.bloodjournal.org From (BSA) for 5 minutes at 45°C, and equilibrated for 10 minutes in 0.1 mol/L Tris-HCl, 0.15 mol/L NaCl pH 7.5. Amplified DNA was detected by incubation with 1:200 anti-DIG Fab alkaline phosphatase (BMH) for 30 minutes at room temperature. The slides were washed in 0.1 mol/L Tris-HCl, 0.15 mol/L NaCl, 0.05 mol/L MgCl 2 pH 9.5 for 5 minutes, and incubated with 0.2 mg/mL NBT, 0.1 mg/mL BCIP at room temperature for up to 1 hour. Color development was monitored under the microscope. The reaction was stopped by washing in water.
RESULTS

RHAMM is expressed by members of the B-lineage hierarchy in myeloma.
Multicolor immunofluorescence was used to determine the expression of RHAMM on MM B and plasma cells (Table 1 and Fig 1) . The majority of MM plasma cells resident in the BM express RHAMM (mean, 66% Ϯ 9%). The MM clone also includes circulating B cells expressing IgH transcripts identical to those of autologous BM plasma cells. [12] [13] [14] Of circulating CD19 ϩ MM B cells, 56% Ϯ 5% expressed RHAMM (Table 1 and Fig 1) . In contrast, of B cells from healthy donors, only 3.5% expressed RHAMM, possibly representing the minority of normal circulating B cells in the early stages of activation in vivo. 22 Sequence analysis of RHAMM gene products. Using cDNA pools from the BM plasma cells of two MM patients and from the B cells of six MM patients, RHAMM cDNA fragments were amplified by RT-PCR with RHAMM-specific primers (Fig 2) . The amplified cDNA fragments were cloned and colonies screened by PCR with the appropriate RHAMM primers to identify those containing potential RHAMM cDNA inserts. Each cloned insert was sequenced and identified as a RHAMM cDNA fragment by alignment with the published sequence of human breast RHAMM. 37 Alignment of RHAMM cDNA fragments produced three distinct RHAMM gene products from B cells and from BM plasma cells designated RHAMM FL , RHAMM Ϫ48 , and RHAMM Ϫ147 (Fig 3) . B-cell and BM plasma cell RHAMM was 99% homologous to breast RHAMM. The two start codons, stop codon, and the two HA-binding domains, previously described for RHAMM, 32, 37 were all present in the Fig 3 (Cont'd) .
1688
CRAINIE , and RHAMM Ϫ147 showed that the RHAMM gene products from these two cell types were 99%   Fig 3 (Cont'd) .
OVEREXPRESSION OF RHAMM IN MYELOMA 1689
homologous. Thus, three distinct RHAMM gene products were identified in MM B and plasma cells by sequence analysis.
Cloning of RHAMM variants. Because the identification of RHAMM FL , RHAMM Ϫ48 , and RHAMM Ϫ147 was performed by sequence alignment of RHAMM cDNA fragments, we confirmed that each variant identified was transcribed into a complete RHAMM message in vivo. The complete ORF of RHAMM was amplified from BM plasma cell cDNA and screened for full-length RHAMM FL , RHAMM Ϫ48 , or RHAMM Ϫ147 clones ( Table 2) . Full-length RHAMM FL , RHAMM Ϫ147 , and RHAMM Ϫ48 clones were initially identified by PCR screening of colonies with primer set 1 (described earlier), which amplifies two products of 613 bp, corresponding to RHAMM FL or RHAMM Ϫ147 , and of 565 bp corresponding to RHAMM Ϫ48 . Next, clones scoring positive for RHAMM FL / RHAMM Ϫ147 were rescreened by PCR with primer set 4, which amplifies two products: one of 666 bp, corresponding to RHAMM FL , and one of 519 bp, corresponding to RHAMM Ϫ147 .
The 519-bp PCR product that characterizes the 147-bp deletion of RHAMM Ϫ147 clones was not amplified from RHAMM Ϫ48 clones rescreened with primer set 4, but the 666-bp product was, showing that the 48-bp and 147-bp deletions are not found in the same RHAMM transcript and that RHAMM Ϫ48 and RHAMM Ϫ147 are distinct RHAMM variants. Figure 4A shows the pattern of PCR products amplified by primer sets 1 and 4 for each RHAMM isoform. A representative clone of each RHAMM isoform was sized by gel electrophoresis to confirm that RHAMM FL , RHAMM Ϫ48 , and RHAMM Ϫ147 were indeed fulllength RHAMM gene products (Fig 4B) . The frequency of transcripts for each isoform expressed in MM was estimated by determining the frequency of clones derived from the ORF amplification (Table 2) . RHAMM FL was the most frequent transcript, appearing in 49% of the randomly selected clones. RHAMM Ϫ48 was present in 47% of the clones, and RHAMM Ϫ147 , detected in 4% of the clones, was relatively infrequent.
RHAMM transcripts from MM cells include exon 4 and have a truncated ''repeat'' region in exon 8. Murine RHAMM has been shown to include an isoform termed RHAMMv4 to designate the presence of exon 4, 26 which is transforming for normal fibroblasts (Fb) and is associated with tumorigenicity. 27 Transformed murine Fb also include a multiple repeat sequence within RHAMM exon 8. 26 In the human, the RHAMM transcript detected in breast epithelium appears to include exon 4 and has only one copy of the ''repeat'' sequence found in mouse Fb. 37 To characterize usage of exon 4 in RHAMM expressed by MM cells, we designed primers to amplify a region spanning cDNA from MM plasma cells was amplified across the ORF and the products cloned; 115 clones were randomly picked and amplified with primer sets 1 and 4 to identify their insert.
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For personal use only. on October 23, 2017. by guest www.bloodjournal.org From exon 4 (primer set 6), such that any transcripts lacking exon 4 would appear as a smaller size than those incorporating exon 4. A single amplification product of 667 bp, incorporating exon 4, was detected in MM B cells and plasma cells (Fig 5A) . No small transcripts were detectable, suggesting that in MM, all RHAMM incorporates exon 4. Using primers spanning exon 8 (primer set 7), a 214-bp product (Fig 5B) indicates transcripts with one repeat sequence, and larger products would indicate transcripts having more than one of the repeated sequence. A single amplification product, of 214 bp, corresponding to a single sequence in the repeat region, was detected in MM B cells and plasma cells (Fig 5B) .
Expression of RHAMM isoforms is detectable in B and plasma cells from all MM patients.
To confirm that RHAMM FL , RHAMM Ϫ48 , and RHAMM Ϫ147 were expressed in B and plasma cells from all myeloma patients, we analyzed the pattern of RHAMM isoforms expressed by the sorted B cells from 11 individual MM patients and BM plasma cells from 11 individual MM patients. Figures 6 and 7 show the pattern of RHAMM isoforms amplified by primer set 1 and primer set 3, respectively. RHAMM FL and RHAMM Ϫ48 were amplified from the B cells of all 11 patients analyzed (six representative patients are shown in Fig 6A, lanes a through f) and from the BM plasma cells of all 11 patients analyzed (five representative patients are shown in Fig 6A and C, lanes g through k) . RHAMM Ϫ147 was amplified from the BM plasma cells of six of six MM patients (Fig 7A, lanes 1 to 6, top panel) and from the B cells of four of five MM patients (Fig 7A, lanes 1 to 5, middle  panel) . Amplification and detection of MM B-cell genomic DNA, under identical conditions, did not generate products corresponding to RHAMM FL , RHAMM Ϫ48 , or RHAMM Ϫ147 , but a genomic interleukin-2 (IL-2) product was amplified with IL-2-specific primers, showing that the RHAMM sequences detected were not amplified genomic products. As an additional control, BM RNA was incubated with or without superscript in the RT step and then amplified; RHAMM amplification products were only detected ''with Superscript'' showing that the RHAMM sequences were derived from RNA and not DNA. Thus, the RHAMM transcripts identified here are expressed by all MM patients.
RHAMM FL and RHAMM Ϫ48 were easily visualized by ethidium bromide staining, while detection of RHAMM Ϫ147 necessitated the increased sensitivity of hybridization to a DIG-labeled RHAMM probe, which suggests that RHAMM Ϫ147 is less abundant in MM B cells and plasma cells than RHAMM FL and RHAMM Ϫ48 , although for one MM patient, 
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RHAMM Ϫ147 was easily detectable by ethidium bromide staining for both B and plasma cells (not shown). Because RHAMM FL and RHAMM Ϫ147 were amplified simultaneously, this suggests that RHAMM Ϫ147 is less abundant in MM B cells and plasma cells than RHAMM FL . However, the conclusion that RHAMM Ϫ147 is generally less abundant than RHAMM FL assumes that RHAMM FL /RHAMM Ϫ147 are amplified equally by primer set 3. To determine whether there was any difference in the efficiency of amplification of RHAMM FL /RHAMM Ϫ147 by primer set 3 or in the efficiency of amplification of RHAMM FL /RHAMM Ϫ48 by primer set 1, we amplified sequential dilutions of cloned RHAMM. Figure 8A shows that equivalent amounts of DNA were amplified by primer set 1 from 100, 10, and 1 pg of RHAMM FL and RHAMM Ϫ48 . Therefore, primer set 1 should equivalently amplify RHAMM FL and RHAMM Ϫ48 transcripts. Figure 8B shows that equivalent amounts of DNA were amplified by primer set 3 from 100 and 10 pg of RHAMM FL and RHAMM Ϫ147 . A longer exposure ( Fig  8C) of the hybridized membrane in Fig 8B shows To evaluate the expression of RHAMM and its splice variants in other B-cell malignancies, transcripts from three malignant B lymphomas and from three B-CLL were analyzed by RT-PCR (Fig 6B and Fig 7B) . B-lymphoma cells have been previously shown to express surface RHAMM as measured by flow cytometry and immunohistochemistry, but B-CLL cells do not express surface RHAMM. 22 RHAMM FL and RHAMM Ϫ48 were detectable for all patients (Fig 6B, lanes m through r) . RHAMM Ϫ147 was detectable for two of three lymphoma patients (Fig 7B, lanes  m and o) and for two of three CLL patients (Fig 7B, lanes q and  r) (Fig 6A, lane l and Fig 6B, lane v) and RHAMM Ϫ147 (Fig 7B, lane v) were not detectable in these polyclonal B cells in Crohn's disease, and RHAMM FL was weakly detectable by hybridization to a DIG-labeled probe ( Fig  7B, lane v) . RHAMM FL and RHAMM Ϫ48 were weakly detected by ethidium bromide staining in B cells from one of eight normal donors (three representative samples are shown in Fig  6B, lanes s through u) . However, use of hybridization to a DIG-labeled RHAMM probe (Fig 7) showed that RHAMM FL transcripts were weakly detectable in populations of B cells from five of eight normal donors (Fig 7A, bottom panel, lanes 1  to 5, and Fig 7B, lanes s through u) . In contrast, amplified RHAMM FL was easily detected in myeloma B cells from 11 of 11 patients by ethidium bromide staining (six representative samples are shown in Fig 6A, lanes a through f) , although at lower levels than those for MM plasma cells, B lymphoma, or B-CLL. The quality of RNA isolated from normal B-cell populations was comparable to that isolated from malignant B-cell populations, because equivalent levels of histone or CD19 transcripts were amplified in all B-cell populations from a separate aliquot of the same cDNA from which RHAMM was amplified (data not shown). This work, together with the phenotypic expression of RHAMM by B-lineage cells in MM (Fig 1) , 17 suggests that most RHAMM ϩ B and plasma cells have downregulated RHAMM mRNA, and/or that these cells have a low RHAMM mRNA copy number. Overall, this analysis indicates that in MM, cells with sufficient RHAMM transcripts to be detected in situ were more abundant in the BM plasma cell population than in the B-cell population, and confirms that detectable RHAMM transcripts are absent from nearly all normal B cells, consistent with their lack of surface RHAMM protein.
DISCUSSION
This study identifies three distinct variants transcribed from the RHAMM gene in MM B and plasma cells. Our results suggest that RHAMM FL , RHAMM Ϫ48 , and RHAMM Ϫ147 are overexpressed in malignant B and plasma cells from myeloma, in B lymphomas, and in B-CLL cells, as compared with resting or chronically activated normal B cells. RHAMM has been linked to oncogenesis, enables the transforming properties of ras mutations in murine systems, 27 and mediates motility of malignant human B cells. 17, 22, 24 The overexpression of RHAMM variants in MM, lymphoma, and CLL implicates them in progression and spread of malignant B cells, and perhaps in the oncogenic events giving rise to myeloma and other B-cell malignancies.
In myeloma, RHAMM FL is virtually identical to the published sequence of human breast RHAMM. 37 In addition, myeloma cells express two novel isoforms, RHAMM Ϫ48 , which has a deletion of 48 bp, and RHAMM Ϫ147 , which has a deletion of 147 bp. These correspond to coding deletions of 16 amino acids (aa) and 49 aa, respectively, in the RHAMM protein. The 48-bp deletion lies between two possible start codons and could alternatively represent a noncoding deletion, in the 5Ј untranslated region of a RHAMM transcript, translated from the second start codon. 
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The significance of the 16-aa and 49-aa deletions to the interaction of RHAMM with HA, a prerequisite for transducing a motile signal, 31 is not readily apparent because these deletions lie outside of the HA-binding domains. The deletion variants may encode conformationally altered RHAMM and/or have a cellular or intracellular localization different from that of RHAMM FL , which is known to be present on the cell surface as a GPI-linked receptor. 26, 27 In MM, surface and intracellular forms of RHAMM are detected, 17 but their correlation with the splice variants identified here is as yet unknown. The nucleotide sequences of the HA-binding domains cloned from MM B and plasma cells translate into a (B[X 7 ]B) HA-binding motif 32, 40 and thus encode two functional HA-binding domains. Because RHAMM appears to be part of an HA receptor complex, 41 and has been shown to interact with src and ras family signaling molecules, 31,42,43 deletion of key regulatory regions would have profound functional consequences that may facilitate malignant processes. Alternatively, deletion of the regions described may modify the affinity of the RHAMM receptor for its ligand, HA. This suggestion is not without precedent, because it has been documented that variant isoforms of the CD44 HA receptor have intact HA-binding domains yet differ in their ability to bind HA. 44 The observation that overexpressed RHAMM is oncogenic in the absence of other known transforming events 27 suggests that RHAMM is unique among adhesion receptors. Although CD44 isoforms are associated with increased metastatic spread, [45] [46] [47] overexpression of CD44 itself has not been associated with oncogenesis. In this context, our observation that all of the RHAMM variants detected here are overexpressed in myeloma cells is provocative. Consistent with previous work showing strong surface expression of RHAMM, RHAMM is also overexpressed in B lymphoma. 22 B-CLL cells, which lack surface RHAMM, 22 have strong expression of RHAMM transcripts for all variants, suggesting that in B-CLL, RHAMM is intracellular. In contrast, resting B cells from normal donors and chronically activated B cells from patients with Crohn's disease, which also lack surface RHAMM (not shown), have undetectable or weakly detectable RHAMM transcripts. In myeloma, the unusual expression of novel RHAMM variants, as well as of RHAMM FL , is consistent with the expression of surface RHAMM by the majority of B and plasma cells in 90 of 90 MM patients, and its relative absence from nearly all normal B cells. Expression of RHAMM appears to be a distinguishing feature of MM, lymphoma, and CLL, as compared with resting or chronically activated normal B cells. 14 RHAMM may be involved in progression and spread of malignant B cells, based on our observations that motility by MM B and leukemic plasma cells is HA-dependent and mediated by RHAMM. 17 However, the RHAMM isoforms involved in the motile process have yet to be identified. RHAMM has been shown to enable transforming mutations of ras; if RHAMM is inactivated by treatment with antisense or by a dominant negative RHAMM, ras-transformed cell lines acquire a normal phenotype and lose their tumorigeneic properties in vivo. 27 Thus, the overexpression of RHAMM in MM and its known role in migratory Our study suggests that at some point during malignant transformation, B cells upregulate, or lose the ability to downregulate RHAMM FL , RHAMM Ϫ48 , and RHAMM Ϫ147 . In so doing, they may acquire the ability to move and metastasize to distant bone marrow sites. The trigger for such a switch is not yet apparent, but ras and RHAMM colocalize on the ruffles in migrating cells, both are involved in signaling via HA, and both are required to convert myeloma cell lines from sessile to motile behavior. 48 Ras is elevated in MM, and, aside from overexpression of RHAMM, ras mutations are the most common oncogenic abnormality in MM. [49] [50] [51] [52] [53] Ras induces metastatic behavior in tumor cells by inducing CD44 variant isoform expression, 54 suggesting it may also play a role in RHAMM expression and alternative splicing. Alternatively, because even wild-type ras is transforming when constitutively targeted to the membrane, 55 deregulated RHAMM may directly or indirectly alter ras localization to give a transformed phenotype.
The molecular characterization of RHAMM isoforms in MM represents a primary step in defining the role RHAMM plays in mediating the metastatic spread of malignant B cells to distant BM sites. In this report, we have shown that overexpression of RHAMM and its splice variants characterizes malignant B and plasma cells. Overexpression and modulation of the balance between soluble, surface, and intracellular RHAMM isoforms may control the regulation of key signaling molecules and the behavioral characteristics of premalignant cells, leading to constitutive stimulation and malignancy.
